Impax Laboratories (IPXL) Sells Daraprim U.S. Rights in $55M Deal

August 10, 2015 6:31 AM

Impax Laboratories (NASDAQ: IPXL) announced that it has sold its U.S. rights to the Daraprim brand to Turing Pharmaceuticals AG ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found